



PRESS RELEASE

PROCEDURES FOR AVAILABILITY AND CONSULTATION OF INFORMATION FOR THE GENERAL MEETING OF 26 JUNE 2015

PROJECT TO COMBINE STALLERGENES AND GREER LABORATORIES

Antony, France, 11 June 2015 – STALLERGENES hereby informs its shareholders that the Ordinary and Extraordinary General Meeting will take place on Friday 26 June 2015, at 2.00 pm, at the Maison de la Mutualité, 24 rue Saint-Victor, 75005 Paris.

The notice of meeting, including the agenda and the resolutions to be voted by the shareholders, was published in the French legal announcements journal, *Bulletin des Annonces Légales Obligatoires* (BALO), on 20 May 2015. The terms and conditions under which shareholders may participate and vote at this General Meeting are contained in this notice.

The background documents and information for this General Meeting are available to shareholders and can be accessed in the Investors – General Meeting section on the Company's website at www.stallergenes.com, in accordance with applicable legal and regulatory provisions.

Amongst other items, shareholders will be asked to vote at the General Meeting of 26 June 2015 on the project to combine the activities of STALLERGENES and GREER LABORATORIES.

On this point, STALLERGENES announces that, at the AMF Board meeting of 9 June 2015, the AMF decided that the terms of the project to combine the operations of STALLERGENES and GREER Laboratories presented to it did not require the implementation of a prior public buyout offer pursuant to Article 236-6 of the AMF General Regulations.

The transaction remains subject to certain other conditions precedent (specified in the information document¹ made public as part of the proposed transaction), notably the approval of the French tax authorities.

According to the current timetable, the transaction could take effect during the third quarter of 2015, following completion of all legal formalities required for implementation.

¹ Page 17.

ABOUT STALLERGENES

STALLERGENES is a global healthcare company specialized in the diagnosis and treatment of allergies. For more than 50 years, STALLERGENES has been continuously expanding the existing frontiers of science in order to provide allergy patients with ever more effective long lasting therapeutic options. Thanks to its innovation strategy, fuelled by investments in research and development amounting to around 20% of total annual revenues as well as external partnerships, STALLERGENES is able to provide targeted allergen immunotherapy-based allergy solutions that significantly improve the lives of allergy patients around the world.

STALLERGENES operates in 23 countries and employs over 1,000 people. In 2014, the Company generated total revenues of €251 million, and more than 500,000 patients were treated with STALLERGENES products.

EURONEXT Paris (Compartment B)
CAC small
ISIN: FR0000065674
Reuters: GEN.PA
Bloomberg: GEN.FP



Forward-looking statements related to STALLERGENES

This press release may contain forward-looking statements concerning the proposed combination and the benefits expected. Such statements are based upon the current beliefs and expectations of Stallergenes' management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

Limitations

This document may not be released, directly or indirectly, in South Africa, Australia, Canada, Japan, New Zealand or the United States of America. The information contained in this document does not constitute an offer to sell or to purchase or the solicitation of an offer to purchase or sell shares or other financial instruments in Ares Allergy Holding or Stallergenes in the United States of America or any other jurisdiction in which such an offer, solicitation, purchase or sale would be unlawful prior to the registration, exemption from registration or other qualification under the terms of legislation on financial instruments in such a jurisdiction. Shares in Ares Allergy Holding have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under any other legislation of any jurisdiction in the United States of America and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act. There will not be any public offering of securities in the United States. Persons in possession of this document are required to inform themselves about and comply with these restrictions. Neither Stallergenes, nor Ares Allergy Holding or any other party to this transaction mentioned in this document accepts any liability in respect of persons who have obtained this document in violation of these restrictions.

Contacts:

Christian Chavy, Chief Executive Officer
Tel. +33 1 55 59 20 04

Investor and analyst relations

Peter Bühler
Chief Financial Officer
Tel: +33 1 55 59 23 22
Email: investorrelations@stallergenes.com

Press relations

Lise Lemonnier
Senior Communication & Public Affairs Director
Tel: + 33 1 55 59 20 96
Email: llemonnier@stallergenes.com

Investor and press relations agency:

Press:

FTI Consulting – Analyst and investor contact
Stephan Dubosq
Tel: +33 1 47 03 68 16
Email: stephan.dubosq@fticonsulting.com

FTI Consulting – Press contact

Anna Adlewska
Tel: +33 1 47 03 68 63
Email: anna.adlewska@fticonsulting.com